Insider trade

Officer sold ~$87K of EW shares in the open market

Traded Jan 9, 2026 · Filed Jan 9, 2026

~$87K
Reported value · 1,019 sh @ $85.7037: 22K
Holds after · shares reported: +0.1%
stock since the trade · S&P 500 +10.1%, $85.13 → $85.19 on Oct 1

Why it stands out

Edwards Lifesciences's CVP, TAVR sold $87K of Edwards Lifesciences shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jan 9, 2026
Reporting period: Not applicable
Filed with the SEC: Jan 9, 2026

Officer$25K–$100KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$87,332

Shares × reported transaction price

Timing vs results

71 days after results of Oct 30, 2025, 32 days before results of Feb 10, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $85.13 on Jan 9, 2026, within 3% of its 52-week high, after a 2% drop over the previous 30 trading days

52-week range $67.07 (Apr 8, 2025) to $86.94 (Dec 29, 2025), 91% of the way up, from 251 adjusted closes. 30 trading days earlier: $86.82 on Nov 25, 2025. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.

Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant

FDA decision near the trade

FDA approved SAPIEN M3 Transcatheter Mitral Valve Replacement System on Dec 22, 2025, 18 days before this trade.

Premarket approval (PMA): Prosthesis, mitral valve, percutaneously delivered. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+0.5%	-2.5%	+3.1%
30 days	-4.4%	-0.5%	-4.0%
90 days	-5.9%	-1.3%	-4.6%
180 days	+10.6%	+7.8%	+2.8%

Past results only. Not a forecast.

Source receipt

Record ID: 0001225208-26-000558
Filed / recorded: Jan 9, 2026, 10:41 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: Edwards Lifesciences Corp
Issuer CIK: 1099800
Ticker: EW
Reporting person: Daniel J. Lippis
Relationship: Officer
Officer title: CVP, TAVR
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Jan 9, 2026
Transaction code: S
Shares / units: 1,019
Price per share: $85.7037
Acquired / disposed: Disposed (D)
Shares owned after: 22,001.9103
Ownership form: Direct
Amendment: No

Footnotes from the filing

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.
This transaction was executed in multiple trades at prices ranging from $85.45 to $85.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of theIssuer, full information regarding the number of shares and prices at which the transaction was effected.